Elevance Health Earnings Call Transcripts
Fiscal Year 2026
-
Q1 results exceeded expectations with strong EPS and revenue growth, driven by ACA seasonality, cost management, and non-recurring investment income. Full-year EPS guidance was raised, and strategic investments in AI and Carelon are supporting operational improvements and long-term growth.
-
CMS sanctions relate to historical risk adjustment practices, with no impact on current operations or 2026 financial objectives. Medicaid and ACA trends are favorable, and strategic investments in AI and digital capabilities are expected to drive efficiency and growth.
Fiscal Year 2025
-
2026 is set as a year of execution and repositioning, with disciplined pricing, targeted investments, and margin stabilization across all segments. Guidance reflects a trough in Medicaid, deliberate Medicare and ACA actions, and confidence in returning to 12%+ EPS growth in 2027.
-
Third quarter results met expectations, with revenue up 12% year-over-year and adjusted EPS reaffirmed at ~$30 for 2025. Medicaid margins remain pressured, with a 125 basis point decline expected in 2026, while investments in technology and Carelon support long-term growth.
-
Adjusted EPS guidance for 2025 was revised to ~$30 due to persistent elevated medical costs in ACA and slower Medicaid rate alignment. Carelon segments showed strong growth, while ACA and Medicaid margins remain pressured. Strategic actions and investments aim to stabilize trends and support long-term growth.
-
The meeting covered director elections, executive compensation, and auditor ratification, with all board proposals passing and a shareholder proposal on diversity reporting failing. Financial results showed revenue and dividend growth, while strategic initiatives focused on value-based care and digital innovation.
-
Q1 2025 results met expectations with strong EPS growth, revenue up 15%, and robust performance across Medicare, Medicaid, and Carelon segments. Guidance for the year is reaffirmed, with Medicaid margin recovery expected in H2 and continued disciplined capital deployment.
-
2025 Medicare Advantage membership guidance is reaffirmed, with stable margins expected despite cost pressures. Medicaid and commercial businesses are performing in line with expectations, while specialty pharmacy trends remain elevated. The CareBridge acquisition expands home-based care capabilities.
Fiscal Year 2024
-
Fourth quarter and full-year results met expectations, with revenue up 3% year-over-year and strong performance in commercial, Medicare Advantage, and ACA exchange segments. 2025 guidance anticipates continued growth, elevated cost trends, and robust capital returns.
-
Investments in AI and digital capabilities, along with strategic M&A, are expected to drive long-term growth. Medicaid and Medicare Advantage margins will remain pressured in 2025, while commercial and ACA segments show strong performance. Carelon's acquisitions and partnerships are expanding capabilities and market reach.
-
Q3 results missed expectations due to elevated Medicaid costs, prompting a reduced full-year EPS outlook. Commercial and Medicare segments remain strong, while Medicaid faces time-bound margin pressure from rate-acuity mismatches. Strategic investments and acquisitions support long-term growth.
-
Q2 adjusted EPS grew 12% year-over-year to $10.12, with full-year guidance reaffirmed. Medicaid and Medicare segments face margin pressure from higher acuity and utilization, but commercial and Carelon businesses are driving growth. Significant investments and acquisitions position the company for long-term expansion.
-
Guidance was reaffirmed with stable trends across all business lines. Strategic partnerships and acquisitions are driving scalable, value-based care and specialty services, while Medicare and commercial businesses focus on disciplined margin improvement and growth. Exchange business continues to expand with healthy margins.